X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis
Thu, 28 Mar

JUBILANT LIFE SCIENCES has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

JUBILANT LIFE SCIENCES Income Statement Analysis

  • Operating income during the year rose 28.3% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 12.9% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 20.2% in FY18 as against 23.0% in FY17.
  • Depreciation charges increased by 42.4% and finance costs decreased by 16.7% YoY, respectively.
  • Other income grew by 61.0% YoY.
  • Net profit for the year grew by 10.4% YoY.
  • Net profit margins during the year declined from 9.8% in FY17 to 8.4% in FY18.

JUBILANT LIFE SCIENCES Income Statement 2017-18

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
Net SalesRs m58,61475,17828.3%
Other incomeRs m24940061.0%
Total RevenuesRs m58,86375,57928.4%
Gross profitRs m13,45315,18412.9%
DepreciationRs m2,9144,15142.4%
InterestRs m3,4112,843-16.7%
Profit before taxRs m7,3768,59116.5%
TaxRs m1,6302,24737.8%
Profit after taxRs m5,7466,34410.4%
Gross profit margin%23.020.2
Effective tax rate%22.126.2
Net profit margin%9.88.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



JUBILANT LIFE SCIENCES Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 20 billion as compared to Rs 17 billion in FY17, thereby witnessing an increase of 19.0%.
  • Long-term debt down at Rs 30 billion as compared to Rs 35 billion during FY17, a fall of 13.0%.
  • Current assets rose 8% and stood at Rs 32 billion, while fixed assets rose 3% and stood at Rs 61 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 96 billion as against Rs 90 billion during FY17, thereby witnessing a growth of 6%.

JUBILANT LIFE SCIENCES Balance Sheet as on March 2018

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
NetworthRs m34,36040,86518.9
 
Current LiabilitiesRs m16,84020,04719.0
Long-term DebtRs m35,05030,478-13.0
Total LiabilitiesRs m90,40796,1766.4
 
Current assetsRs m29,48131,8988.2
Fixed AssetsRs m 58,90560,7153.1
Total AssetsRs m90,40796,1766.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



JUBILANT LIFE SCIENCES Cash Flow Statement Analysis

  • JUBILANT LIFE SCIENCES's cash flow from operating activities (CFO) during FY18 stood at Rs 13 billion, an improvement of 2.7% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -6 billion, an improvement of 37.1% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs -9 billion on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -2 billion from the Rs 1 billion net cash flows seen during FY17.

JUBILANT LIFE SCIENCES Cash Flow Statement 2017-18

ParticularsNo. of months1212% Change
Year EndingMar-17Mar-18
Cash Flow from Operating ActivitiesRs m12,68513,0322.7%
Cash Flow from Investing ActivitiesRs m-4,504-6,177-
Cash Flow from Financing ActivitiesRs m-6,859-9,011-
Net Cash FlowRs m1,172-2,123-
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for JUBILANT LIFE SCIENCES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 40.7, an improvement from the EPS of Rs 36.9 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 658.7, stands at 12.6 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.1 times, while the price to sales ratio stands at 1.7 times.
  • The company's price to cash flow (P/CF) ratio stood at 10.0 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Sales per share (Unadj.)Rs376.3482.6
TTM Earnings per shareRs36.940.7
Diluted earnings per shareRs36.139.8
Price to Cash Flow x11.810.0
TTM P/E ratiox12.412.6
Price / Book Value ratiox2.53.1
Market CapRs m102,585104,910
Dividends per share (Unadj.)Rs3.03.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for JUBILANT LIFE SCIENCES

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 1.6x during FY18, from 1.8x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 4.0x during FY18, from 3.2x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 15.5% during FY18, from 16.7% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 16.0% during FY18, from 15.5% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 9.6% during FY18, from 10.1% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Current ratiox1.81.6
Debtors’ DaysDays6355
Interest coveragex3.24.0
Debt to equity ratiox1.00.7
Return on assets%10.19.6
Return on equity%16.715.5
Return on capital employed%15.516.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how JUBILANT LIFE SCIENCES has performed over the last 5 years, please visit here.

JUBILANT LIFE SCIENCES Share Price Performance

Over the last one year, JUBILANT LIFE SCIENCES share price has moved up from Rs 839.8 to Rs 658.7, registering a loss of Rs 181.2 or around 21.6%.

(To know more, check out historical annual results for JUBILANT LIFE SCIENCES and quarterly results for JUBILANT LIFE SCIENCES)

Equitymaster requests your view! Post a comment on "JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - MYLAN COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS